首页> 美国卫生研究院文献>Cellular and Molecular Immunology >HMGB1 contributes to allergen-induced airway remodeling in a murine model of chronic asthma by modulating airway inflammation and activating lung fibroblasts
【2h】

HMGB1 contributes to allergen-induced airway remodeling in a murine model of chronic asthma by modulating airway inflammation and activating lung fibroblasts

机译:HMGB1通过调节气道炎症和激活肺成纤维细胞在慢性哮喘的小鼠模型中促进变应原诱导的气道重塑

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The pro-inflammation factor high-mobility group box protein 1 (HMGB1) has been implicated in the pathogenesis of asthma. In this study, we used a murine model of chronic asthma to evaluate the effects of HMGB1 on airway remodeling. Female BALB/c mice were randomly divided into four groups: control, ovalbumin (OVA) asthmatic, OVA+isotype antibody and OVA+anti-HMGB1 antibody. Anti-HMGB1 antibody therapy was started on day 21 and was administered three times per week for 6 weeks before intranasal challenge with OVA. In this mouse model, HMGB1 expression is significantly elevated. The anti-HMGB1 antibody group exhibited decreased levels of immunoglobulin E (IgE) and inflammatory mediators and reduced inflammatory cell accumulation, airway hyperresponsiveness (AHR), mucus synthesis, smooth muscle thickness and lung collagen content compared with the OVA groups. Treatment with HMGB1 increased proliferation, migration, collagen secretion and α-smooth muscle actin (SMA) expression in MRC-5 cells. Treatment with the HMGB1/IL-1β complex significantly increased the expression and secretion of transforming growth factor (TGF-β1), matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF). Altogether, these results suggest that blocking HMGB1 activity may reverse airway remodeling by suppressing airway inflammation and modulating lung fibroblast phenotype and activation.
机译:促炎因子高迁移率族蛋白1(HMGB1)与哮喘的发病机制有关。在这项研究中,我们使用慢性哮喘的小鼠模型来评估HMGB1对气道重塑的影响。将雌性BALB / c小鼠随机分为四组:对照组,哮喘卵白蛋白(OVA),OVA +同型抗体和OVA +抗HMGB1抗体。抗HMGB1抗体疗法于第21天开始,在经OVA鼻腔攻击之前每周进行3次共6周的治疗。在此小鼠模型中,HMGB1表达显着升高。与OVA组相比,抗HMGB1抗体组的免疫球蛋白E(IgE)和炎症介质水平降低,炎症细胞积聚,气道高反应性(AHR),粘液合成,平滑肌厚度和肺胶原含量降低。 HMGB1处理可增加MRC-5细胞的增殖,迁移,胶原蛋白分泌和α-平滑肌肌动蛋白(SMA)表达。 HMGB1 /IL-1β复合物治疗可显着增加转化生长因子(TGF-β1),基质金属蛋白酶(MMP)-9和血管内皮生长因子(VEGF)的表达和分泌。总之,这些结果表明,阻断HMGB1活性可能会通过抑制气道炎症并调节肺成纤维细胞表型和激活来逆转气道重塑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号